Breast Cancer

VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts…

The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based…

Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!

The San Antonio Breast Cancer Symposium (SABCS) took place on the 7-10 December 2021, both virtually and in-person. We heard…

Check out our top picks from ESMO 2021!

VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

VJOncology presents highlights from this year’s virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress!

VJOncology are excited to present some key abstracts and trial updates announced at this year’s virtual St. Gallen Breast Cancer…

The de-escalation and treatment personalization of patients with early breast cancer has advanced in recent years, with studies such as…

Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab…

The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…

The Enhanced Recovery After Surgery (ERAS) approach was initially pioneered for colorectal surgery by a group of surgeons in northern…

Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast…

It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first…

Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten…